DelveInsight’s, “Cervical cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Cervical cancer Understanding
    Cervical cancer: Overview
    Cervical cancer develops in a woman’s cervix (the entrance to the uterus from the vagina). Almost all Cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact. Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause Cervical cancer in women. Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with Cervical cancer worldwide and about 311 000 women died from the disease. Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most Cervical cancer cases. When diagnosed, Cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care.

    "Cervical cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical cancer pipeline landscape is provided which includes the disease overview and Cervical cancer treatment guidelines. The assessment part of the report embraces, in depth Cervical cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Cervical cancer R&D. The therapies under development are focused on novel approaches to treat/improve Cervical cancer.

    Cervical cancer Emerging Drugs Chapters
    This segment of the Cervical cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Cervical cancer Emerging Drugs
    • Cemiplimab: Regeneron Pharmaceuticals
    Cemiplimab (Libtayo) is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Currently, it is in Phase III stage of development to treat Cervical cancer.
    • AK104: Akesobio
    AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is based on Akeso’s proprietary “TETRABODY” technology and simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. AK104 is in a tetrameric form, which is designed to bind to PD-1 and CTLA-4 simultaneously to achieve the efficacy of PD-1 and CTLA-4 combination blockade with lower toxicity.
    • Durvalumab: Celgene
    Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumour’s immune-evading tactics. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination in multiple cancer types. Currently, it is in Phase III stage of development to treat Cervical cancer.
    Further product details are provided in the report??..

    Cervical cancer: Therapeutic Assessment
    This segment of the report provides insights about the different Cervical cancer drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Cervical cancer
    There are approx. 70+ key companies which are developing the therapies for Cervical cancer. The companies which have their Cervical cancer drug candidates in the most advanced stage, i.e. phase III include, Regeneron Pharmaceuticals.
    • Phases
    DelveInsight’s report covers around 70+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Cervical cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • intravenous
    • Subcutaneous
    • Topical.
    • Molecule Type

    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Cervical cancer: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical cancer therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical cancer drugs.

    Cervical cancer Report Insights
    • Cervical cancer Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Cervical cancer Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Cervical cancer drugs?
    • How many Cervical cancer drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical cancer?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical cancer therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Cervical cancer and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Regeneron Pharmaceuticals
    • Akesobio
    • Celgene
    • AstraZeneca
    • ImaginAb Inc
    • Genexine, Inc.
    • Merck KGaA
    • Seagen Inc.
    • Vaccibody AS
    • Qilu Pharmaceutical Co., Ltd.
    • Genor Biopharma Co., Ltd.
    • Agenus Inc.
    • Immunitor LLC
    • Genentech
    • Guangzhou Gloria Biosciences Co., Ltd.
    • Lee’s Pharmaceutical Limited
    • BeiGene
    • Henlix Biotech
    • Biocad
    • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    • Cellid Co., Ltd.
    • Innovent Biologics
    • Zeria Pharmaceutical
    • Advaxis, Inc.
    • Human Genome Sciences
    • Hookipa Biotech GmbH
    • Eli Lilly and Company
    • SK Bioscience Co., Ltd.
    • Tesaro, Inc
    • Iovance Biotherapeutics, Inc.
    • NETRIS Pharma
    • Advenchen Laboratories, LLC
    • Rubius Therapeutics
    • Repertoire Immune Medicines
    • Bristol-Myers Squibb
    • Sotio a.s.
    • VM Oncology, LLC
    • Andes Biotechnologies
    • Transgene
    • Xencor, Inc.
    • Exelixis
    • Ocellaris Pharma, Inc
    • Fate Therapeutics
    • Arcus Biosciences, Inc.
    • MacroGenics

    Key Products
    • Cemiplimab
    • AK104
    • Durvalumab
    • MEDI 0457
    • 89Zr Df IAB 22M2C
    • GX-188E
    • M7824
    • Tisotumab Vedotin
    • VB10.16
    • QL1604
    • GB226
    • AGEN2034
    • V3-Cervix
    • Tiragolumab
    • GLS-010
    • ZKAB001
    • Tislelizumab
    • HLX10
    • BCD-100
    • SG001
    • BVAC-C
    • IBI310
    • Z-100
    • ADXS11-001
    • Mapatumumab
    • HB-201
    • Gemzar
    • NBP615
    • Niraparib
    • LN-145
    • NP137
    • AL3818
    • RTX-321
    • RPTR-168
    • BMS-986340
    • SO-C101
    • VMD-928
    • Andes-1537
    • TG4001
    • XmAb?23104
    • XB002
    • OC-001
    • FT 500
    • AB308
    • MGD013